Frontier Biotechnologies Inc. (SHA:688221)

Market Cap	8.06B
Revenue (ttm)	133.15M
Net Income (ttm)	-189.80M
Shares Out	374.58M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000,982
Average Volume	38,468,908
Open	21.82
Previous Close	22.42
Day's Range	21.18 - 23.56
52-Week Range	4.48 - 24.67
Beta	1.00
RSI	64.62
Earnings Date	Aug 30, 2025

About R1 RCM

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health in China. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 302
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688221

Financial Performance

In 2024, Frontier Biotechnologies's revenue was 129.47 million, an increase of 13.32% compared to the previous year's 114.25 million. Losses were -201.38 million, -38.78% less than in 2023.